137 related articles for article (PubMed ID: 37678277)
21. Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial.
Yang H; Xu L; Guan S; Hao X; Ge Z; Tong F; Cao Y; Liu P; Zhou B; Cheng L; Liu M; Liu H; Xie F; Wang S; Peng Y; Wang C; Wang S
BMC Cancer; 2022 Dec; 22(1):1357. PubMed ID: 36577958
[TBL] [Abstract][Full Text] [Related]
22. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
23. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study.
Mizushima T; Ikeda M; Kato T; Ikeda A; Nishimura J; Hata T; Matsuda C; Satoh T; Mori M; Doki Y
BMC Cancer; 2019 Sep; 19(1):929. PubMed ID: 31533662
[TBL] [Abstract][Full Text] [Related]
24. XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).
Zhu XD; Huang MZ; Wang YS; Feng WJ; Chen ZY; He YF; Zhang XW; Liu X; Wang CC; Zhang W; Ying JE; Wu J; Yang L; Qin YR; Luo JF; Zhao XY; Li WH; Zhang Z; Qiu LX; Geng QR; Zou JL; Zhang JY; Zheng H; Song XF; Wu SS; Zhang CY; Gong Z; Liu QQ; Wang XF; Xu Q; Wang Q; Ji JM; Zhao J; Guo WJ
Cancer Commun (Lond); 2022 Apr; 42(4):314-326. PubMed ID: 35212487
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
[TBL] [Abstract][Full Text] [Related]
26. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
Fazio N; Biffi R; Maibach R; Hayoz S; Thierstein S; Brauchli P; Bernhard J; Stupp R; Andreoni B; Renne G; Crosta C; Morant R; Chiappa A; Luca F; Zampino MG; Huber O; Goldhirsch A; de Braud F; Roth AD; ;
Ann Oncol; 2016 Apr; 27(4):668-73. PubMed ID: 26712905
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer.
Yaghobi Joybari A; Azadeh P; Babaei S; Hosseini Kamal F
Pathol Oncol Res; 2019 Oct; 25(4):1599-1605. PubMed ID: 30712194
[TBL] [Abstract][Full Text] [Related]
28. A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma.
Petersen PC; Petersen LN; Vogelius I; Bjerregaard JK; Baeksgaard L
Acta Oncol; 2021 Jul; 60(7):948-953. PubMed ID: 34086514
[TBL] [Abstract][Full Text] [Related]
29. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
30. Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial.
Jiang Z; Xie Y; Zhang W; Du C; Zhong Y; Zhu Y; Jiang L; Dou L; Shao K; Sun Y; Xue Q; Tian Y; Gao S; Zhao D; Zhou A
Gastric Cancer; 2024 May; 27(3):571-579. PubMed ID: 38457083
[TBL] [Abstract][Full Text] [Related]
31. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
Zhu J; Liu F; Gu W; Lian P; Sheng W; Xu J; Cai G; Shi D; Cai S; Zhang Z
Radiat Oncol; 2014 Mar; 9():70. PubMed ID: 24606870
[TBL] [Abstract][Full Text] [Related]
32. A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial.
Chen MH; Lin J; Hsiao CF; Shan YS; Chen YC; Chen LT; Liu TW; Li CP; Chao Y
Medicine (Baltimore); 2016 Jan; 95(3):e2565. PubMed ID: 26817912
[TBL] [Abstract][Full Text] [Related]
33. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
34. A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis.
Wang Y; Yu YY; Li W; Feng Y; Hou J; Ji Y; Sun YH; Shen KT; Shen ZB; Qin XY; Liu TS
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1155-61. PubMed ID: 24748418
[TBL] [Abstract][Full Text] [Related]
35. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Goel G; Jauhri M; Negi A; Aggarwal S
Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537
[TBL] [Abstract][Full Text] [Related]
36. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
Peng L; Yang W; Zhang Z; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
[TBL] [Abstract][Full Text] [Related]
37. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
Kang YK; Yook JH; Park YK; Lee JS; Kim YW; Kim JY; Ryu MH; Rha SY; Chung IJ; Kim IH; Oh SC; Park YS; Son T; Jung MR; Heo MH; Kim HK; Park C; Yoo CH; Choi JH; Zang DY; Jang YJ; Sul JY; Kim JG; Kim BS; Beom SH; Cho SH; Ryu SW; Kook MC; Ryoo BY; Kim HK; Yoo MW; Lee NS; Lee SH; Kim G; Lee Y; Lee JH; Noh SH
J Clin Oncol; 2021 Sep; 39(26):2903-2913. PubMed ID: 34133211
[TBL] [Abstract][Full Text] [Related]
38. Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer.
Satake H; Kondo M; Mizumoto M; Kotake T; Okita Y; Ogata T; Hatachi Y; Yasui H; Miki A; Imai Y; Ichikawa C; Murotani K; Kotaka M; Kato T; Kaihara S; Tsuji A
Anticancer Res; 2017 Jul; 37(7):3703-3710. PubMed ID: 28668863
[TBL] [Abstract][Full Text] [Related]
39. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
40. [Effects of XELOX regimen as neoadjuvant chemotherapy on radical resection rate and prognosis in patients with advanced gastric cancer].
Zhao Q; Li Y; Tan BB; Tian Y; Jiao ZK; Zhao XF; Zhang ZD; Wang D; Yang PG
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):773-7. PubMed ID: 24378101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
